SCHEMBL2695437

SCHEMBL2695437

O=Cc1ccc(S(=O)(=O)N(Cc2ncc[nH]2)Cc2ncc[nH]2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 1/20 0.44
HCRTR2 O43614 1/20 0.44
TAAR1 Q96RJ0 6/20 0.43
CYP2D6 P10635 1/20 0.40
TSHR P16473 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.39
LMNA P02545 2/20 0.39
GLA P06280 1/20 0.39
BLM P54132 1/20 0.39
PMP22 Q01453 1/20 0.39
KMT2A Q03164 1/20 0.38
ALDH1A1 P00352 2/20 0.35
CNR2 P34972 1/20 0.35
NPC1 O15118 1/20 0.35
GAA P10253 1/20 0.35
KCNA5 P22460 1/20 0.35
HTT P42858 2/20 0.35
CXCR3 P49682 1/20 0.34
HTR2B P41595 1/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2127047 0.75 CYP2D6 (0.46) TAAR1CYP2D6TSHRSMN1; SMN2LMNA
SCHEMBL7299851 0.72 TAAR1 (0.62) TAAR1CYP2D6TSHRSMN1; SMN2LMNA
SCHEMBL1792401 0.72 CXCR4 (0.54) TAAR1CYP2D6TSHRSMN1; SMN2LMNA
SCHEMBL1792306 0.71 CXCR4 (0.50) HCRTR1HCRTR2TAAR1CYP2D6TSHR
SCHEMBL4777900 0.71 CXCR4 (0.45) TAAR1CYP2D6TSHRSMN1; SMN2LMNA
SCHEMBL1793549 0.71 CXCR4 (0.67) HCRTR1HCRTR2TAAR1CNR2
SCHEMBL2802110 0.70 LMNA (0.68) TSHRSMN1; SMN2LMNAKMT2AALDH1A1
SCHEMBL4922448 0.70 ALDH1A1 (0.55) TSHRLMNAKMT2AALDH1A1CNR2
SCHEMBL30274545 0.69 CA9 (0.58) SMN1; SMN2LMNAKMT2AALDH1A1NPC1
SCHEMBL8906501 0.69 NPC1 (0.45) SMN1; SMN2LMNAKMT2AALDH1A1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8519124-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2013-08-27 US disclosed
EP-1961744-B1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO (JP) 2013-04-17 EP disclosed
US-20120207765-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2012-08-16 US disclosed
US-8168783-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2012-05-01 US disclosed
US-20090169567-A1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO., LTD., (JP) 2009-07-02 US disclosed
EP-1961744-A1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2008-08-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090169567-A1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF CXCR4, CXCL12, CXCR3 HCRTR1 1035/4885HCRTR2 1558/4885TAAR1 1730/4885
US-20120207765-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF CXCR4, CXCR3, CXCR1 HCRTR1 473/4885HCRTR2 661/4885TAAR1 686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.